LIFEMD ($LFMD) posted quarterly earnings results for Q4 2025 on Monday, March 9th. The company reported earnings of -$0.04 per share, missing estimates of -$0.03 by $0.01. The company also reported revenue of $46,870,000, missing estimates of $49,544,082 by $-2,674,082.
Stock price change since market close: +10.58%
You can see Quiver Quantitative's $LFMD stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
LIFEMD Insider Trading Activity
LIFEMD insiders have traded $LFMD stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $LFMD stock by insiders over the last 6 months:
- NICHOLAS P ALVAREZ (Chief Acquisition Officer) sold 75,000 shares for an estimated $443,760
- JESSICA FRIEDEMAN (Chief Marketing Officer) sold 15,000 shares for an estimated $54,157
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
LIFEMD Hedge Fund Activity
We have seen 52 institutional investors add shares of LIFEMD stock to their portfolio, and 95 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NUVEEN, LLC removed 1,224,091 shares (-92.5%) from their portfolio in Q4 2025, for an estimated $4,174,150
- CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. removed 925,685 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $6,285,401
- FEDERATED HERMES, INC. added 721,018 shares (+278.1%) to their portfolio in Q4 2025, for an estimated $2,458,671
- PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. added 687,328 shares (+inf%) to their portfolio in Q4 2025, for an estimated $2,343,788
- MORGAN STANLEY removed 649,552 shares (-66.6%) from their portfolio in Q4 2025, for an estimated $2,214,972
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 434,937 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $2,953,222
- POINT72 ASSET MANAGEMENT, L.P. added 399,094 shares (+inf%) to their portfolio in Q4 2025, for an estimated $1,360,910
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
LIFEMD Analyst Ratings
Wall Street analysts have issued reports on $LFMD in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Keybanc issued a "Overweight" rating on 11/19/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/19/2025
- BTIG issued a "Buy" rating on 11/18/2025
- Lake Street issued a "Buy" rating on 11/18/2025
- B. Riley Securities issued a "Buy" rating on 11/18/2025
To track analyst ratings and price targets for LIFEMD, check out Quiver Quantitative's $LFMD forecast page.
LIFEMD Price Targets
Multiple analysts have issued price targets for $LFMD recently. We have seen 6 analysts offer price targets for $LFMD in the last 6 months, with a median target of $8.5.
Here are some recent targets:
- Steven Valiquette from Mizuho set a target price of $6.0 on 11/19/2025
- Yi Chen from HC Wainwright & Co. set a target price of $9.0 on 11/19/2025
- Steve Dechert from Keybanc set a target price of $8.0 on 11/19/2025
- David Larsen from BTIG set a target price of $10.0 on 11/18/2025
- Brooks O'Neil from Lake Street set a target price of $8.0 on 11/18/2025
- William Woods from B. Riley Securities set a target price of $10.0 on 11/18/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
